Carlsmed, Inc. (CARL) Stock Price & Analysis
Carlsmed, Inc. (CARL) fell 2.37% to USD 15.23 as of September 9, 2026 at 11:43 UTC, according to Nexqual real-time market data.
CARL last closed at USD 15.6; the session ranged USD 15.01–15.37 on volume of 63,788 shares. Market capitalization is $415.82M, with a 52-week range of USD 8.5–17.23 (NMS). Source: Nexqual, September 9, 2026 at 11:43 UTC.
Key Statistics (as of September 9, 2026 at 11:43 UTC)
| Price | USD 15.23 |
|---|---|
| Change | ▼ 2.37% (down) |
| Previous Close | USD 15.6 |
| Open | USD 15.37 |
| Day Range | USD 15.01 – 15.37 |
| 52-Week Range | USD 8.5 – 17.23 |
| Volume | 63,788 shares |
| Market Cap | $415.82M |
| Exchange | NMS |
Technical Analysis (CARL)
Nexqual's technical model rates CARL "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of September 9, 2026 at 11:43 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 56.41 (neutral) |
| vs SMA50 | Above (USD 13.42) |
| MACD | 0.73 (positive) |
Analyst Ratings (CARL)
Wall Street analysts rate CARL "None" based on 5 analysts, with a mean price target of USD 19.2 (range USD 17–23), per Nexqual as of September 9, 2026 at 11:43 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 19.2 |
| High Target | USD 23 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CARL)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $19.17M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.39 vs est -0.4 ▲ beat |
| 2026-03-31 | USD -0.26 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.43 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.49 ▲ beat |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Financials & Fundamentals (CARL)
| Total Revenue | $63.30M |
|---|---|
| Revenue Growth (YoY) | +56.70% |
| Gross Margin | +76.63% |
| Operating Margin | -58.27% |
| Profit Margin | -57.42% |
| ROE | -66.14% |
| Debt / Equity | 26.02 |
| Current Ratio | 8.84 |
| Total Cash | $89.22M |
| Total Debt | $21.92M |
| Free Cash Flow | $-26.41M |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Financial Health Score (CARL)
Nexqual rates Carlsmed, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 11:43 UTC.
| Growth | Strong — Revenue +57% YoY (latest Q) |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -58% |
| Balance Sheet | Strong — $89M cash vs $22M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Critical — ROE -66%, ROA -28.2% |
Ownership (CARL)
| Insider Ownership | +44.42% |
|---|---|
| Institutional Ownership | +40.38% |
| Shares Outstanding | 27.30M |
| Float | 15.67M |
| Short % of Float | +12.87% |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Leadership (CARL)
Carlsmed, Inc. is led by Michael John Cordonnier (age 48), Co-Founder, Chairman, CEO & President, per Nexqual as of September 9, 2026 at 11:43 UTC.
| Co-Founder, Chairman, CEO & President | Michael John Cordonnier (age 48) |
|---|---|
| Co-Founder, Chief Intellectual Property Officer & Director | Niall Patrick Casey (age 48) |
| CFO & Treasurer | Leonard M. Greenstein (age 49) |
| Chief Technology Officer | Shariq Hussain |
| Senior Vice President of People & Culture | Jodi Allen Coe |
Major Backers & Investors (CARL)
Notable institutional backers of Carlsmed, Inc. include Jupiter Topco LLC, JANUS INVESTMENT FUND-Janus Henderson Venture Fund, Parkman Healthcare Partners LLC, according to Nexqual as of September 9, 2026 at 11:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 4.58% |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 3.69% |
| Parkman Healthcare Partners LLC | 2.19% |
| KCM Capital Inc | 1.61% |
| Pier Capital, LLC | 1.37% |
| Millennium Management | 1.08% |
| Palumbo Wealth Management Llc | 0.98% |
| Schonfeld Strategic Advisors Llc | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.73% |
| Vanguard Group | 1.72% |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
From Carlsmed, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.
- The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
- Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HTFL | Heartflow, Inc. | USD 47.75 | ▼ 3.94% |
| KMTS | Kestra Medical Technologies, Lt | USD 25.64 | ▲ 1.97% |
| BBNX | Beta Bionics, Inc. | USD 19.33 | ▼ 2.96% |
| CBLL | CeriBell, Inc. | USD 24.31 | ▼ 1.06% |
| OMDA | Omada Health, Inc. | USD 22.18 | ▼ 0.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 11:43 UTC. This page is informational and not investment advice.